Stay updated with breaking news from 75915k10. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Regulus Therapeutics Inc. (NASDAQ:RGLS – Get Free Report) has earned an average recommendation of “Moderate Buy” from the five analysts that are currently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating on the company. The average 12 month […]
HC Wainwright reiterated their buy rating on shares of Regulus Therapeutics (NASDAQ:RGLS – Free Report) in a research report released on Monday morning, Benzinga reports. The brokerage currently has a $9.00 target price on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for Regulus Therapeutics’ Q1 2024 earnings at ($0.19) EPS, Q2 2024 earnings […]
Regulus Therapeutics Inc. (NASDAQ:RGLS – Get Free Report) saw a large increase in short interest in March. As of March 15th, there was short interest totalling 5,130,000 shares, an increase of 9,244.3% from the February 29th total of 54,900 shares. Based on an average daily volume of 2,870,000 shares, the days-to-cover ratio is currently 1.8 […]
StockNews.com initiated coverage on shares of Regulus Therapeutics (NASDAQ:RGLS – Get Free Report) in a research note issued on Tuesday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock. Regulus Therapeutics Price Performance RGLS opened at $1.51 on Tuesday. The business’s 50-day moving average is $1.33 and its two-hundred day moving average is […]
StockNews.com started coverage on shares of Regulus Therapeutics (NASDAQ:RGLS – Get Free Report) in a research note issued to investors on Tuesday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock. Regulus Therapeutics Trading Up 3.4 % NASDAQ RGLS opened at $1.53 on Tuesday. The firm’s fifty day simple moving average is $1.33 […]